Mineral wool

Global Building Thermal Insulation (Glass Wool, Mineral Wool, EPS, XPS, Cellulose) Market Size, Share, Trends Analysis and Forecasts Report 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 6, 2023
Construction & Property, Other Construction & Property, Plastic, XPS, Little League World Series (Middle East-Africa Region), Construction, Foam glass, Telephone numbers in Hungary, Glass wool, Mineral wool, USD, Acoustics, Roof, School, Hospital, Sanitation, Water, Air conditioning, Growth, EPS, Glass, Compressive strength, Electrical wiring, Floor, Cellulose

The "Building Thermal Insulation Market Size, Share & Trends Analysis Report By Product (Glass Wool, Mineral Wool, EPS, XPS, Cellulose), By Application (Roof, Walls, Floor), By End-use,By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Building Thermal Insulation Market Size, Share & Trends Analysis Report By Product (Glass Wool, Mineral Wool, EPS, XPS, Cellulose), By Application (Roof, Walls, Floor), By End-use,By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global building thermal insulation market size is expected to reach USD 44.69 billion by 2030, expanding at 4.5% CAGR from 2023 to 2030.
  • Thermal insulation materials help reduce the heat buildup within the buildings, thus resulting in lower dependence on air conditioning.
  • EPS product segment accounted for 31% of the global building thermal insulation industry share in 2022.

Molecular Templates, Inc. Reports Fourth Quarter 2022 Financial Results and Business Update

Retrieved on: 
Thursday, March 30, 2023
PD, Orange County Convention Center, Neoplasm, RECIST, Section 13, Capillary leak syndrome, Patient, Investment, Therapy, Immunogenic cell death, TD, Symantec Endpoint Protection, Security agreement, Lung cancer, CD8, HIV disease progression rates, Bristol Myers Squibb, TME, ETB 4, IND, PD-L1, Conference, Safety, CD38, HLA, HER2, Aes, MHC, Cancer, American Association for Cancer Research, NSCLC, Immunoglobulin A, Antibody, CMV, Webcast, ETB, Pembrolizumab, Workforce, Genotype, Immunomodulatory imide drug, Security, Toxic epidermal necrolysis, Tumor microenvironment, BCMA, Pharmaceutical industry, Medical imaging, Palladium, Cement, Vaccine, Mineral wool, Breast

Revenues for the fourth quarter of 2022 were $2.6 million, compared to $18.0 million for the same period in 2021.

Key Points: 
  • Revenues for the fourth quarter of 2022 were $2.6 million, compared to $18.0 million for the same period in 2021.
  • Revenues for the fourth quarter of 2022 were comprised of revenues from collaborative research and development agreements with Bristol Myers Squibb.
  • Total research and development expenses for the fourth quarter of 2022 were $17.6 million, compared with $19.3 million for the same period in 2021.
  • Total general and administrative expenses for the fourth quarter of 2022 were $6.1 million, compared with $7.9 million for the same period in 2021.

Agenus’ Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian Cancer

Retrieved on: 
Monday, March 27, 2023
Biotechnology, Infectious Diseases, Health, Clinical Trials, Oncology, Inc., Society, SGO, Beth Israel Deaconess Medical Center, Infection, Cancer, Platinum, SITC, Gynecologic Oncology (journal), Society of Gynecologic Oncology, NSCLC, Biomarker, Publication, Lung cancer, Immunotherapy, Harvard Medical School, Patient, Colorectal cancer, Melanoma, Ovarian cancer, Conference, ORR, Safety, Vaccine, Mineral wool

These findings, presented in an oral plenary session at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, showed a 33% overall response rate (ORR).

Key Points: 
  • These findings, presented in an oral plenary session at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, showed a 33% overall response rate (ORR).
  • “The remarkable efficacy and manageable tolerability profile of this combination suggest a transformative potential for ovarian cancer patients.”
    The ovarian cancer cohort is part of a large study evaluating the safety, efficacy, and dose optimization of botensilimab alone and in combination with balstilimab in multiple solid tumors.
  • Agenus is currently enrolling in Global Phase 2 ACTIVATE trial programs in metastatic microsatellite stable colorectal cancer , melanoma and pancreatic cancers .
  • A total of 24 evaluable patients with recurrent platinum resistant/refractory ovarian cancer received either 1 or 2 mg/kg botensilimab every 6 weeks and 3 mg/kg balstilimab every 2 weeks.

North America Building Thermal Insulation Market Analysis Report 2023-2030: Key Players are Focusing on Developing Cost-effective Products with Enhanced Properties to Remain Competitive - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 22, 2023
Other Construction & Property, Energy, Construction & Property, Other Energy, XPS, IECC, Construction, LEED, International Energy Conservation Code, Glass wool, Mineral wool, Temperature, USD, Primary energy, Government, Roof, Investment, Cellulose, International Energy Agency Energy in Buildings and Communities Programme, Growth, Heat, EPS, U.S. Green Building Council, Glass, Glass fiber, Renewable energy, Floor

The North America building thermal insulation market is forecast to reach USD 15.47 billion by 2030 and register a CAGR of 3.5% from 2023 to 2030.

Key Points: 
  • The North America building thermal insulation market is forecast to reach USD 15.47 billion by 2030 and register a CAGR of 3.5% from 2023 to 2030.
  • Favorable government policies coupled with increasing awareness among consumers are expected to remain the key driving factor for the growth of the building thermal insulation market in North America.
  • The players in the North America building thermal insulation market focus on increasing their market share through organic growth, rather than mergers and acquisitions.
  • Companies in the market are focusing on expanding their product portfolio by developing cost-effective insulation products with enhanced properties.

NextCure Provides Business Update and Reports Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 2, 2023
AML, Research, Cancer, Patient, Public expenditure, Extracellular matrix, B7-H4, Pharmaceutical industry, Medical imaging, Mineral wool, Cryptocurrency

BELTSVILLE, Md., March 02, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided a business update and reported full year 2022 financial results.

Key Points: 
  • BELTSVILLE, Md., March 02, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided a business update and reported full year 2022 financial results.
  • Continued enrollment in the Phase 1b dose expansion study in patients with solid tumors and high expression of B7-H4.
  • Financial Results for Full Year Ended December 31, 2022
    Cash, cash equivalents, and marketable securities as of December 31, 2022, were $159.9 million as compared to $219.6 million as of December 31, 2021.
  • The change in net loss from the previous year was primarily due to higher research and development expenses.

AssetWise PCL (SET: ASW) strengthens ties with Takara Leben, launches B1.35bn development in Atmoz Flow Minburi

Retrieved on: 
Wednesday, March 1, 2023
ASEAN, KAVE, Housing, BHT, Pink Line, ESTA, Hospital, Partnership, Running, ASW, HONOR, Kasetsart University, Employment, Pink Line (Bangkok), Mineral wool, Min Buri district

Atmoz Flow Minburi is situated near the Pink Line MRT mass transit system and is easily accessible by the Minburi Market Station.

Key Points: 
  • Atmoz Flow Minburi is situated near the Pink Line MRT mass transit system and is easily accessible by the Minburi Market Station.
  • Atmoz Flow Minburi is expected to be up and running in the fourth quarter of this year and starting to recognise revenue by then.
  • According to ASW Chief Executive Officer Kromchet Vipanpong, ASW holds a 51% share in Atmoz Flow Minburi venture with Takara Leben taking a 49% share.
  • Atmoz Flow Minburi comes with a complete common facility to meet the life-styles of residents of all generations for living together perfectly.

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides a Pipeline Update

Retrieved on: 
Tuesday, February 28, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Death, CD73, Safety, KIT, Cancer, TIGIT, PD-1, NYSE, Research, Lung cancer, Risk, G&A, Interim, Phase II, Standard of care, Patient, R, OS, Progression-free survival, Inflammation, Research and development, ORR, Docetaxel, NSCLC, GI, Partnership, PFS, CRPC, Administration, Taiho Pharmaceutical, Lung, Pharmaceutical industry, Mineral wool, Cryptocurrency, Taiho

“During 2022, Arcus established itself as a late-stage company and made tremendous progress in the advancement of its pipeline.

Key Points: 
  • “During 2022, Arcus established itself as a late-stage company and made tremendous progress in the advancement of its pipeline.
  • There are also four ongoing Phase 2 studies to evaluate domvanalimab-based combinations: three in NSCLC and one in upper GI cancer.
  • In the fourth-quarter 2022, Arcus recognized $26 million in license and development service revenues for programs optioned by Gilead.
  • G&A expenses were $104 million for the full-year 2022, compared to $72 million for the same period in 2021.

Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 28, 2023
Well, GUF, GMP, IND, UAS7, AAAAI, Allergy, Patient, B cell, Cold urticaria, Inflammation, Research, Prurigo nodularis, R, Hypersensitivity, SRS, SD, Rockefeller University, D, ILT4, G&A, UCT, Prurigo, PD-1, Cell, Kinetics, Myelocyte, Aes, Growth, Hives, Gilead Sciences, Safety, American Academy, Eosinophilic esophagitis, Skin, KIT, Survival, Disease, CSU, Drug development, Annual general meeting, Omalizumab, Contingency, Pharmaceutical industry, Vaccine, Aluminium, Mineral wool, Cryptocurrency, Dermatology

HAMPTON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.

Key Points: 
  • HAMPTON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.
  • Celldex believes her deep background in drug development strongly complements the current Board’s skills and experiences.
  • Barzolvolimab is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity.
  • The litigation settlement related loss had a ($0.32) impact on net loss per share for the twelve months ended December 31, 2022.

Ultra Lithium Assays Up to 417 ppm Lithium in Drill Hole at the Laguna Verde Brine Lithium Project in Argentina

Retrieved on: 
Tuesday, February 28, 2023
Lithium, Round 2, TSX, SGS, News, Magnesium, NI, Laboratory, PH, MASL, Salt, Boron, ULT, Noetics, Cenozoic, Metal, OTCQB, Bangladesh Petroleum Exploration and Production Company Limited, Silviculture, Copper, Mineral wool, Potassium

VANCOUVER, British Columbia, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ultra Lithium Inc. ( TSX-V:ULT, OTCQB: ULTXF and Frankfurt: QFB ) (“Ultra Lithium” or “the Company”) is pleased to announce the brine sampling results from a drill hole at its 100% owned Laguna Verde brine lithium project in Catamarca Province, Argentina.

Key Points: 
  • VANCOUVER, British Columbia, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ultra Lithium Inc. ( TSX-V:ULT, OTCQB: ULTXF and Frankfurt: QFB ) (“Ultra Lithium” or “the Company”) is pleased to announce the brine sampling results from a drill hole at its 100% owned Laguna Verde brine lithium project in Catamarca Province, Argentina.
  • Drill hole LV22-04 assayed up to 417 parts per million (“ppm” or “mg/L”) lithium (Li) from two rounds of sampling completed in January – February 2023.
  • The Laguna Verde project is the flagship project of the Company and one of the Company’s 100% owned brine lithium projects in Argentina.
  • Lithium (Li) values are in the range of 256 ppm to 354 ppm with an average of 324 ppm.

Building Thermal Insulation Market to be Worth $44.69 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Wednesday, February 22, 2023
EPS, Construction, Little League World Series (Middle East-Africa Region), Hospital, Sanitation, Water, XPS, Foam glass, Mineral wool, Air conditioning, Roof, Volume, Acoustics, Compressive strength, Glass, School, Glass wool, USD, Growth, SAN, Research, Plastic, Telephone numbers in Hungary, Renewable energy, Glass fiber, Cellulose, Floor

Thermal insulation materials help reduce the heat build-up within the buildings, thus resulting in lower dependence on air conditioning.

Key Points: 
  • Thermal insulation materials help reduce the heat build-up within the buildings, thus resulting in lower dependence on air conditioning.
  • Key Industry Insights & Findings from the report:
    EPS product segment accounted for 31% of the global building thermal insulation industry share in 2022.
  • Grand View Research has segmented the global building thermal insulation market based on product, application, end-use, and region.
  • Building Thermal Insulation Market - Product Outlook (Volume, Kilotons; Revenue, USD Million, 2018 - 2030)